Cline, Davis & Mann launches CDM World Agency

Share this article:
Cline, Davis & Mann is going global with the launch of CDM World Agency, an international healthcare agency network with offices in Europe and Brazil and plans to expand into China, Japan, Mexico and Canada.

The global network will launch with offices in London, Paris, Munich, Barcelona, Madrid, Istanbul and Sao Paulo. CDM plans to open offices in China, Japan, Switzerland, Italy, Canada and Mexico this year. CDM World Agency will be headed by Eric Berkeley, who joined the network last year as director of global operations from DDB, where he held a similar role.

“For a long time, clients have been requiring that we have a global network,” said Cline, Davis & Mann chairman and CEO Ed Wise. “Now they are actually doing business that way. What clients are looking for is a higher level of control, and we wanted to elevate the network to be aligned along a single P&L and be a single agency around the world.”

Cline, Davis & Mann is headquartered in New York, with other US offices in Princeton, NJ, and Los Angeles.  

CDM has cobbled together the global offices over a year, with acquisitions of new*performance in Munich, Adding Targis in Madrid, Tagare in Sao Paulo, Intro in Istanbul and a merger in London.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...